COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
26 hedge funds and large institutions have $4.22M invested in COSCIENS Biopharma Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
236% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $347K
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.05% less ownership
Funds ownership: 0.14% → 0.09% (-0.05%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
60% less capital invested
Capital invested by funds: $10.6M → $4.22M (-$6.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$161K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$84.2K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$54.3K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$45.1K |
| 5 |
Two Sigma Advisers
New York
|
+$41.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$1.25M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$795K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$777K |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$296K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$239K |
CSCI Hedge Fund Activity: Q2 2019 in Review
26 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2019, worth a combined $4.22M — down 60% from $10.6M a quarter earlier.
Fund positioning in CSCI was balanced in Q2 2019: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $161K. The largest seller was J. Goldman & Co, cutting an estimated $1.25M.
- 26 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $4.22M of COSCIENS Biopharma Inc. Common Stock stock for Q2 2019, down 60% quarter-over-quarter.
- 6 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2019 and 6 closed out, a net change of 0 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $161K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2019 was J. Goldman & Co, an estimated $1.25M sold.
Based on aggregated 13F filings for Q2 2019.